Q4 2018 13F Holders as of 31 Dec 2018
-
Type / Class
-
Equity / COM
-
Number of holders
-
132
-
Total 13F shares, excl. options
-
45,941,687
-
Shares change
-
+1,437,310
-
Total reported value, excl. options
-
$1,098,891,390
-
Value change
-
+$30,175,470
-
Put/Call ratio
-
60%
-
Number of buys
-
70
-
Number of sells
-
-65
-
Price
-
$23.92
Significant Holders of AIMMUNE THERAPEUTICS INC - COM (AIMT) as of Q4 2018
175 filings reported holding AIMT - AIMMUNE THERAPEUTICS INC - COM as of Q4 2018.
AIMMUNE THERAPEUTICS INC - COM (AIMT) has 132 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 45,941,687 shares
.
Largest 10 shareholders include PRICE T ROWE ASSOCIATES INC /MD/ (4,771,909 shares), BlackRock Inc. (3,723,111 shares), Vanguard Group Inc (3,675,074 shares), Foresite Capital Management II, LLC (2,968,649 shares), FMR LLC (2,099,221 shares), Aisling Capital LLC (1,990,000 shares), ALLIANCEBERNSTEIN L.P. (1,945,670 shares), STATE STREET CORP (1,908,094 shares), WELLINGTON MANAGEMENT GROUP LLP (1,860,951 shares), and EVENTIDE ASSET MANAGEMENT, LLC (1,739,000 shares).
This table shows the top 132 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.